Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02817997Recruiting

International Registry for Patients With Castleman Disease

Role: collaborator

NCT05316116Early Phase 1Terminated

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Role: collaborator

NCT04191421Phase 1Completed

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Role: collaborator

NCT06485947Phase 1Recruiting

Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

Role: collaborator

NCT02308527Phase 2Active Not Recruiting

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Role: collaborator

All 5 trials loaded